Allergan Aesthetics, a subsidiary of AbbVie, recently unveiled promising findings at the American Academy of Dermatology meeting, presenting data on their investigational neurotoxin TrenibotE and insights into the aesthetic concerns of patients undergoing GLP-1 agonist treatment for weight loss. In an 18-week, open-label Phase 3 study, TrenibotE demonstrated a consistent safety profile with no new safety concerns or neutralizing antibody development, showing rapid onset of effects as early as eight hours, although with a shorter duration of approximately two to three weeks.

These findings are significant for the longevity and healthspan research community as they highlight the evolving landscape of aesthetic treatments, particularly for individuals undergoing weight management therapies. The survey data revealed that over half of GLP-1 patients expressed concerns about their facial appearance during treatment, indicating a potential market for aesthetic interventions tailored to this demographic. The barriers to accessing such care, primarily cost and fears of unnatural results, underscore the need for targeted solutions that address both the aesthetic and psychological aspects of aging and weight management.

One key takeaway from this presentation is the potential for integrating aesthetic treatments like TrenibotE into the care plans for patients on GLP-1 therapies. As the patient population is predominantly younger and female, there is an opportunity for practitioners to bridge the gap between weight loss and aesthetic satisfaction, ultimately enhancing the overall healthspan experience for these individuals. This intersection of dermatology and metabolic health may pave the way for innovative therapeutic strategies that address both physical appearance and long-term well-being.

Source: longevity.technology